2016 saw the lowest number of new PPPs since BioCentury started tracking
BioCentury’s sixth annual analysis of public-private partnerships (PPPs) shows the lowest number of new alliances in 2016 since tracking began. The decline is a stark contrast to the enthusiasm of 2012, suggesting partners are becoming more selective about how best to bridge academia and industry.
While the data show little change among the top companies, almost all of the top academic institutions increased their activity in 2016 over the year before.
Stakeholders who spoke with BioCentury note there is still widespread enthusiasm in industry for using PPPs as a vehicle for external innovation. However, the learnings of the last few years show there’s a need to innovate the PPP model, and the field is continually experimenting with alternative ways to design the alliances. In particular, the complexities of setting up the deals and running the partnerships have underscored the importance of properly defining the goals a priori, and of investing in project management (see “Managing Goliaths”).
BioCentury Innovations defines a PPP as a preclinical research-based collaboration between at least